A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2011
12/08/2011	US20110301153 Methods of treating cancer
12/08/2011	US20110301152 Nicotinic receptor agonists for the treatment of inflammatory diseases
12/08/2011	US20110301151 Dimeric iap inhibitors
12/08/2011	US20110301150 Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
12/08/2011	US20110301149 Compositions and methods for treating alcohol use disorders, pain and other diseases
12/08/2011	US20110301148 Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
12/08/2011	US20110301147 Modified release preparations containing oxcarbazepine and derivatives thereof
12/08/2011	US20110301146 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
12/08/2011	US20110301145 Pyridazinones, method of making, and method of use thereof
12/08/2011	US20110301144 Kinase Antagonists
12/08/2011	US20110301143 Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
12/08/2011	US20110301142 Antagonists of lysophosphatidic acid receptors
12/08/2011	US20110301141 Aminopyrimidine derivatives as lrrk2 inhibitors
12/08/2011	US20110301140 Pyridine Carboxamide orexin Receptor Antagonists
12/08/2011	US20110301139 Pharmaceutical compositions of cefixime
12/08/2011	US20110301138 process to make fusidic acid cream
12/08/2011	US20110301137 Dermaceutical gel made using sodium fusidate and a process to make it
12/08/2011	US20110301136 Nitrate Esters Of Corticoid Compounds Useful As Diuretics
12/08/2011	US20110301135 Stabilization of glucocorticoid esters with acids
12/08/2011	US20110301134 Alkyne antagonists of lysophosphatidic acid receptors
12/08/2011	US20110301133 Compositions of protein receptor tyrosine kinase inhibitors
12/08/2011	US20110301132 Methods of treating urethritis and related infections using fusidic acid
12/08/2011	US20110301131 Drug Delivery Implants and Processes for Their Preparation
12/08/2011	US20110301130 Topical composition for the treatment of actinic keratosis
12/08/2011	US20110301129 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
12/08/2011	US20110301128 Pyrrole Derivatives As Pharmaceutical Agents
12/08/2011	US20110301127 Methods of reducing microbial resistance to drugs
12/08/2011	US20110301125 Method for Treating Macular Degeneration
12/08/2011	US20110301124 Proteasome inhibitors
12/08/2011	US20110301122 Heteroaromatic compounds for use as hif inhibitors
12/08/2011	US20110301121 Hydrogel of polysaccharide derivative
12/08/2011	US20110301120 Use of a chitosan polymer for heparin neutralization
12/08/2011	US20110301119 Pharmaceutical compositions containing fucoidan for stimulating and activating osteogenesis
12/08/2011	US20110301118 Methods of treatment utilising glucan formulations
12/08/2011	US20110301117 Cryogenic skin cream and method
12/08/2011	US20110301116 Nsaids-induced gastrointestinal mucosal disorder alleviator and manufacturing method thereof
12/08/2011	US20110301115 Methods of Treating Subclinical Sun Damage
12/08/2011	US20110301114 Amphiphile prodrugs
12/08/2011	US20110301113 Pyridineamine derivatives
12/08/2011	US20110301112 Fused ring thrombin receptor antagonists
12/08/2011	US20110301111 Cyclic adenosine monophosphates for reducing the formation of adhesions
12/08/2011	US20110301110 TRIM33 (TIF1gamma) AS A NEW DIAGNOSTIC MARKER OF CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
12/08/2011	US20110301109 Phenylpyrimidone Compounds, the Pharmaceutical Compositions, Preparation Methods and Uses Thereof
12/08/2011	US20110301108 Materials and methods for sensitizing multidrug resistant cells
12/08/2011	US20110301107 Derivatives of morphine-6-glucuronide, preparation method thereof and use of same in therapeutics
12/08/2011	US20110301106 Use of Icariside II in Manufacture of Products for Preventing or Treating Male or Female Sexual Dysfunction
12/08/2011	US20110301105 Compositions for proliferation of cells and related methods
12/08/2011	US20110301104 Transition state structure of orotate phosphoribosyl transferases and uses thereof
12/08/2011	US20110301103 Methods of Treatment
12/08/2011	US20110301100 Pharmaceutical Compositions Comprising Polyethylene Glycol Having a Molecular Weight of Less Than 600 Daltons
12/08/2011	US20110301099 Method for enhancing penetration of lipid insoluble medicaments through cell membranes using small S-Allyl-containing molecules with phospholipid permeability as carrier molecules
12/08/2011	US20110301095 Methods and compositions for assessing and treating metastasis, metastatic cancer, and potential for metastasis
12/08/2011	US20110301094 New tumor suppressor gene, p28ing5
12/08/2011	US20110301085 Protein hydrolysate and plant sterol containing composition for improving serum lipid profile and preventing atherosclerosis
12/08/2011	US20110301083 Conjugate based systems for controlled drug delivery
12/08/2011	US20110301082 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
12/08/2011	US20110301078 Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems
12/08/2011	US20110301031 Spiroheterocyclic n-oxypiperidines as pesticides
12/08/2011	US20110301029 Composition and Method for Improving Plant Health
12/08/2011	US20110300578 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110300577 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production
12/08/2011	US20110300247 Flaxseed lignan complex and its use thereof
12/08/2011	US20110300245 Topical, palatable, anti-inflammatory and analgesic for specific application to intraoral, gingival and extraoral areas correlated with, and related to, the trigeminal nerve and its nerve branches and plexus. To mitigate, attenuate or prevent migraine-type headache, cluster-type headache, tension-type headache, post-traumatic headache, atypical facial pain and cervical muscle spasm as well as other idiopathic head or facial pain or discomfort, associated with, or exacerbated by, inflammation
12/08/2011	US20110300241 Oral care compositions for treating xerostomia
12/08/2011	US20110300239 Blood flow improving agent
12/08/2011	US20110300237 Protective solutions for organs
12/08/2011	US20110300236 Method of treating impaired mitochondrial function
12/08/2011	US20110300234 Methods of Treating Tumor Cells Using RHCC Protein, Fragment or Variant
12/08/2011	US20110300232 EFFECTS OF NITRIC OXIDE (NO) AND iNOS ON EXPRESSION AND SIGNAL TRANSDUCTION IN CANCER AND ITS USE IN DRUG DISCOVERY AND CANCER THERAPY DESIGN
12/08/2011	US20110300229 Treating or preventing rotavirus infection
12/08/2011	US20110300227 Malignant neoplasm treatment protocol
12/08/2011	US20110300225 Nutritional compositions with coated lipid globules
12/08/2011	US20110300224 Taste masked dosage form of pharmaceutically acceptable salt of escitalopram
12/08/2011	US20110300221 Therapeutic Inhibitor of Vascular Smooth Muscle Cells
12/08/2011	US20110300220 Solid calcium lactate in substantially spherical form
12/08/2011	US20110300219 Nanostructures for drug delivery
12/08/2011	US20110300218 Novel solid state forms of ranolazine salts
12/08/2011	US20110300217 Hydromorphone therapy
12/08/2011	US20110300216 Chewable, swallowable and effervescent solid dosage form for oral delivery of pharmaceutical actives
12/08/2011	US20110300214 Pharmaceutical compositions comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid
12/08/2011	US20110300213 Oral formulations of bipolar trans carotenoids
12/08/2011	US20110300211 Soft-gelatin capsule formulation
12/08/2011	US20110300210 Controlled release nanoparticulate clozapine compositions
12/08/2011	US20110300209 Modified release solid pharmaceutical compositions of trimetazidine and process thereof
12/08/2011	US20110300207 Method of treating post-surgical acute pain
12/08/2011	US20110300205 Self replicating rna molecules and uses thereof
12/08/2011	US20110300204 Nutritional compositions with large lipid globule size
12/08/2011	US20110300202 Medical item for long term durg release
12/08/2011	US20110300195 Ophthalmic Compositions Comprising Calcineurin Inhibitors or mTOR Inhibitors
12/08/2011	US20110300190 Compound, composition and uses thereof
12/08/2011	US20110300187 Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof
12/08/2011	US20110300186 Functionalized Nano- and Micro-materials for Medical Therapies
12/08/2011	US20110300184 Pharmaceutical compositions for treating or preventing bone conditions
12/08/2011	US20110300182 Nucleic acid drug for treatment of allergic disease
12/08/2011	US20110300175 Composition for promoting control of total and ldl cholesterol, and/or weight loss and/or thermogenesis
12/08/2011	US20110300165 Substituted isoxazole compounds
12/08/2011	US20110300164 Immunostimulatory dna:rna oligonucleotides
12/08/2011	US20110300155 Modulating xrn2
12/08/2011	US20110300154 Treatment of airway hyperreactivity
12/08/2011	US20110300152 Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels

1 ... 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 ... 7860